Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Cohance Lifesciences's
Operating Income
for the
three
months ended in Jun. 2026 was ₹-484 Mil. Cohance Lifesciences's Interest Expense for the
three
months ended in Jun. 2026 was ₹-67 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Cohance Lifesciences's Interest Coverage or its related term are showing as below:
NSE:COHANCE'
s Interest Coverage Range Over the Past 10 Years
Min: 3.68 Med: 43.04 Max: 94.86
Current: 3.68
NSE:COHANCE's Interest Coverage is ranked worse than 77.47% of 679
companies
in the Drug Manufacturers industry
Industry Median: 12.99
vs NSE:COHANCE: 3.68
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Cohance Lifesciences Interest Coverage Related Terms
Cohance Lifesciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Cohance Lifesciences did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Cohance Lifesciences (NSE:COHANCE) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cohance Lifesciences and its competitors. Over the past decade, Cohance Lifesciences' Interest Coverage has ranged from 3.68 to 94.86. According to the industry distribution chart, Cohance Lifesciences ranks #526 out of 679 companies in the Drug Manufacturers industry, placing it in the top 77.5%.
Is Cohance Lifesciences' Interest Coverage too high?
Cohance Lifesciences' current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 3.68 to a high of 94.86. Based on the distribution chart, Cohance Lifesciences ranks #526 out of 679 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cohance Lifesciences has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #526 out of 679 companies for Interest Coverage. This places Cohance Lifesciences in the lower half of its industry. The industry median Interest Coverage is 12.99. Historically, Cohance Lifesciences' own Interest Coverage has ranged from 3.68 to 94.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.99, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (NSE:COHANCE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹798.35, compared to a current price of ₹455.95 — trading 42.9% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Cohance Lifesciences' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Cohance Lifesciences (NSE:COHANCE), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (NSE:COHANCE) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹455.95 is trading 42.9% below its estimated GF Value™ of ₹798.35.
GuruFocus considers Cohance Lifesciences to be Significantly Undervalued.
Key valuation signals for NSE:COHANCE:
Interest Coverage: 0 (At Loss)
GF Value™: ₹798.35 vs. price of ₹455.95 (42.9% below fair value)
No single metric tells the full story. See the NSE:COHANCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
82GF Score
Get the complete analysis for NSE:COHANCE
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:COHANCE has been successfully added to your 
